Drugs / GLPG1205
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04704739 | Jan → Mar 2021 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT04532567 | Aug → Dec 2020 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03102567 | Oct 2016 → Feb 2017 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02623296 | Oct 2015 → Feb 2016 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02143856 | May → Jul 2014 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT01887106 | Jun → Sep 2013 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT03725852 | Sep 2018 → Jul 2020 | idiopathic pulmonary fibrosis | Lakefront Biotherapeutics NV | Completed | Missed primary |
| Phase 2 | NCT02337608 | Dec 2014 → Sep 2015 | ulcerative colitis | Lakefront Biotherapeutics NV | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-01-26 | Lakefront Biotherapeutics NV | Results Galapagos reports results with GLPG1205 in ulcerative colitis lakefrontbio.com ↗
The ORIGIN study results showed that GLPG1205 did not statistically significantly differentiate from placebo on (partial) Mayo scores. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-07-09 | Lakefront Biotherapeutics NV | Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF lakefrontbio.com ↗ |
| 2016-01-26 | Lakefront Biotherapeutics NV | Galapagos reports results with GLPG1205 in ulcerative colitis lakefrontbio.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLPG1205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01887106 ↗ |
| Action | Inhibit | “GLPG1205 is a selective functional antagonist of G-protein-coupled receptor 84” PMID 36328358 ↗ Mar 2023 |
| Modality | Small molecule | — CHEMBL3716365 ↗ |
| Route | Oral | “single ascending oral doses of GLPG1205” NCT01887106 ↗ |
| Target | GPR84 | “Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes” PMID 33955686 ↗ May 2021 |